Jun Sungmin, Lee Jong Jin, Park Seol Hoon, Kim Tae Yong, Kim Won Bae, Shong Young Kee, Ryu Jin-Sook
Department of Nuclear Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea,
Ann Nucl Med. 2015 Aug;29(7):603-12. doi: 10.1007/s12149-015-0983-5. Epub 2015 May 17.
A diffuse hepatic uptake (DHU) on radioiodine whole-body scans (WBS) after (131)I therapy is caused by (131)I-labeled iodoproteins, particularly (131)I-labeled thyroglobulin (Tg). We hypothesized that the DHU intensity after (131)I therapy might correlate with subsequent serum Tg reduction, suggesting that DHU reflects destruction of functioning thyroid tissue as measured by serum Tg.
We retrospectively reviewed the medical records and (131)I WBSs of 47 patients treated with (131)I therapy for distant metastasis from differentiated thyroid cancer (M:F = 15:32, median age 45 years, range 11-74 years). All patients received post-ablative (131)I scans (PAWBS) at first (131)I ablation after total thyroidectomy and post-therapy (131)I scan (PTWBS) at second (131)I therapy. The DHU intensities of the PAWBS and PTWBS were classified into 3 grades: 1, faint; 2, modest; and 3, intense. Serum thyroid-stimulating hormone-stimulated Tg (sTg) levels were measured at the time of each therapy and 1 year after the second (131)I therapy.
One year after the second (131)I therapy, 10 patients (21.3%) were in remission and 37 (78.7%) had persistent disease. The DHU intensity on PAWBS correlated with the percentage sTg reduction at the next follow-up point (σ = 0.466, p = 0.0016). The patients with intense DHU on PTWBS tended to have a higher percentage sTg reduction than the other patients, although statistical significances were marginal (Spearman's rank correlation: σ = 0.304, p = 0.054; Kruskal-Wallis test: p = 0.067). In univariate analysis, the DHU grades on PAWBS and the initial sTg levels were significantly different between patients in remission and those with persistent disease (PAWBS: p = 0.022; initial sTg: p = 0.0059). In multivariate logistic regression analysis, after adjusting for initial sTg levels, a DHU grade of 3 on PAWBS was an independent predictor of remission (PAWBS: p = 0.028; initial sTg <100 ng/ml: p = 0.043).
In patients with iodine-avid distant metastases, intensity of DHU on (131)I post-therapy scan correlated with subsequent percentage serum sTg reduction. Also, intense DHU could be one of the predictors of remission in these patients.
碘-131全身扫描(WBS)后出现的弥漫性肝脏摄取(DHU)是由碘-131标记的碘蛋白引起的,尤其是碘-131标记的甲状腺球蛋白(Tg)。我们推测碘-131治疗后的DHU强度可能与随后血清Tg的降低相关,这表明DHU反映了通过血清Tg测量的功能性甲状腺组织的破坏。
我们回顾性分析了47例接受碘-131治疗分化型甲状腺癌远处转移患者的病历和碘-131 WBS(男∶女 = 15∶32,中位年龄45岁,范围11 - 74岁)。所有患者在全甲状腺切除术后首次碘-131消融时接受消融后碘-131扫描(PAWBS),在第二次碘-131治疗时接受治疗后碘-131扫描(PTWBS)。PAWBS和PTWBS的DHU强度分为3级:1级,微弱;2级,中等;3级,强烈。在每次治疗时以及第二次碘-131治疗后1年测量血清促甲状腺激素刺激的Tg(sTg)水平。
第二次碘-131治疗后1年,10例患者(21.3%)缓解,37例(78.7%)疾病持续存在。PAWBS上的DHU强度与下一个随访点sTg降低的百分比相关(σ = 0.466,p = 0.0016)。PTWBS上DHU强烈的患者sTg降低的百分比往往高于其他患者,尽管统计学意义不显著(Spearman等级相关性:σ = 0.304,p = 0.054;Kruskal-Wallis检验:p = 0.067)。在单因素分析中,缓解患者和疾病持续存在患者之间PAWBS上的DHU分级和初始sTg水平有显著差异(PAWBS:p = 0.022;初始sTg:p =